Business Context and Reporting Period
This Form 8-K Current Report was filed by Simulations Plus, Inc. on August 23, 2024. The filing reports on leadership changes implemented to optimize the Company's business units.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes.
Material Changes
The primary material change reported is the departure of Dr. Brett Howell, Ph.D., who served as President, Quantitative Systems Pharmacology. His departure is effective August 30, 2024.
Guidance, Outlook, and Risks
Management Commentary: The leadership changes are part of an initiative to optimize business units. A press release detailing these changes is included as Exhibit 99.1.
Compensatory Arrangements: Dr. Howell entered into a separation agreement providing for twelve (12) months' severance and related separation benefits. His employment agreement was terminated.
Risks and Forward-Looking Statements: The filing includes standard cautionary language regarding forward-looking statements. Actual results may differ materially from expectations due to known and unknown risks, uncertainties, and other factors.
Investor Verification Checklist
- Verify the effective date of Dr. Brett Howell's departure (August 30, 2024).
- Review the separation agreement terms, specifically the 12-month severance package.
- Examine Exhibit 99.1 (Press Release) for additional details on the business unit optimization strategy.
- Confirm if a successor has been named for the President, Quantitative Systems Pharmacology role.